Joshua Liang (Clover)
Fueled by Covid prospects, Chinese vaccine developer scores $230M to upscale the whole pipeline
The Covid tides are floating more than US or European boats.
Take Clover Biopharmaceuticals, the Chengdu, China-based developer of a CEPI-funded vaccine that’s just closed $230 million in a Series C. That means the biotech is officially $400 million richer than it was before the pandemic struck — and potentially standing much closer to the commercial market.
“Over the last 12 months, we have grown our headcount from ~175 FTEs in China to now ~500 FTEs across over a dozen countries,” CEO Joshua Liang told Endpoints News in an email.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
